A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)

OBJECTIVES: In the largest head-to-head comparison between an oral and an intravenous (IV) iron compound in patients with inflammatory bowel disease (IBD) so far, we strived to determine whether IV iron isomaltoside 1,000 is non-inferior to oral iron sulfate in the treatment of iron deficiency anemi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Reinisch, Walter, Staun, Michael, Tandon, Rakesh K, Altorjay, Istvan, Thillainayagam, Andrew V, Gratzer, Cornelia, Nijhawan, Sandeep, Thomsen, Lars L
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2013
Soggetti:
Inflammatory Bowel Disease
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3853365/
https://ncbi.nlm.nih.gov/pubmed/24145678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2013.335
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi